APR 2021 APR 2 0 18 SEP 2 0 18 OCT 2 0 18 DEC 2 0 18 JAN 2 0 19 Allogene acquires Pfizer’s allogeneic CAR T portfolio and closes one of the largest Series A rounds in biotechnology history— $300 million from a premier investment consortium that includes Two River, TPG, Vida Ventures, Bellco Capital, the University of California Office of the Chief Investment Officer of the Regents, Gilead, and Pfizer Public company debut, raising $372.6 million in gross proceeds in the second largest biotechnology IPO of 2018 Completes $120 million in private financing 100th employee joins FDA clears investigational new drug (IND) application, setting the stage for the Phase 1/2 ALPHA clinical trial of ALLO-501, an anti-CD19 AlloCAR T™ products in patients with relapsed/refractory non-Hodgkin lymphoma FEB 2 0 19 Kicks off process to build state-of-the-art AlloCAR T™ manufacturing facility in Newark, California MAY 2 0 19 MAY 2020 Presents initial Phase 1 ALLO-501 ALPHA trial data DEC 2020 Presents initial Phase 1 ALLO-715 UNIVERSAL trial data FDA clears IND applications for ALLO-316 in renal cell carcinoma and ALLO-715 in combination with nirogacestat in r/r MM Construction complete on manufacturing facility, Cell Forge 1 FDA clears IND application for ALLO-605, the first TurboCAR™ candidate for the treatment of r/r MM FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-715, an AlloCAR T™ cell therapy in development for r/r MM MAY 2021 Presents Phase 1 data on ALLO-501 and ALLO-501A Presents PK/PD data on ALLO-647 FDA clears IND application to study second indication of therapy, the UNIVERSAL study of ALLO-715, an AlloCAR T™ products targeting BCMA in patients with relapsed/ refractory multiple myeloma (r/r MM) JUL 2 0 21 for ALLO-605, Allogene’s first TurboCAR TM , targeting BCMA in multiple myeloma FDA clears IND application FDA grants Fast Track designation for ALLO-605 2021 FDA grants orphan drug designation for ALLO-715 AUG
